Drug Trial Radar · NCT04987671
Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
14
Planned (sponsor's estimate)
Start
Aug 5, 2021
Primary completion
May 11, 2022
Study completion Sep 2023
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic effect after a single dose or at steady state after multiple doses of AMX0035 in adults with sporadic ALS.
Conditions
- ALS
Interventions
AMX0035Drug
Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood concentration of PB and taurursodiolTime frame: Between Day 1 and Day 40
- Systemic exposure to PB and taurursodiolTime frame: Between Day 1 and Day 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Norman Fixel Institute for Neurological Diseases
Gainesville, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.